Long-Term Multi-center Evaluation of E-Poly and Regenerex
- Conditions
- Osteoarthritis of HipTraumatic Arthritis of Hip
- Interventions
- Procedure: Total Hip Arthroplasty
- Registration Number
- NCT00545285
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
There are two distinct aims of this study:
1. This prospective study is designed to document the long-term (10-year) radiographic and clinical outcomes of a new type of highly cross-linked polyethylene liner which contains vitamin E as an anti-oxidant, (E-Poly), in a group of primary total hip arthroplasty subjects. The clinical outcome of E-Poly will be compared to a group of subjects receiving Arcom XL polyethylene.
2. This study is also designed to document the long-term (10-year) radiographic and clinical outcomes of a new cementless acetabular component having a titanium porous surface (Regenerex). The clinical outcome of this new FDA cleared device will be compared a group of subjects receiving an acetabular component having a plasma sprayed surface.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
- Subjects requiring primary total hip replacement
- Subjects with diagnosis of osteoarthritis or traumatic arthritis
- Subjects who demonstrate the ability to return for follow-up for the next 10 years
- Subjects with limited life span
- Subjects with difficulty in comprehending study protocol for any reason.
- Subjects with inflammatory disease, previous infection or those requiring revision hip surgery.
- Subjects with avascular necrosis
- Subjects whose bony structures are so small that a femoral head less than 32mm in diameter must be used.
- Subjects whose bony structure deviates substantially from the general norm sufficiently to require non-standard techniques and non-standard implants. Specific examples of these are total dislocation of the hip, severe coxa vera deformity, severe forms of multiple epiphyseal dysplasia
- Subjects with complex disease entities which significantly increase the risks of the surgery such as any major platelet abnormality, hematological disorder, positive for HIV or any other major medical complication which substantially reduces longevity.
- Female subjects that are pregnant or who may suspect they are pregnant or who plan to become pregnant while participating in this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Total Hip Arthroplasty Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell 3 Total Hip Arthroplasty Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell 4 Total Hip Arthroplasty Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell 1 Total Hip Arthroplasty Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
- Primary Outcome Measures
Name Time Method Survivorship: length of time implant remains without revision Evaluated at 1,3,5,7 ,10th year over 10 years Complications and Adverse Events Evaluated at 1,3,5,7 ,10th year over 10 years Incidence of radiolucencies (acetabular component) Evaluated at 1,3,5,7 ,10th year over 10 years Patient administered Outcome Survey scores Evaluated at 1,3,5,7 ,10th year over 10 years Polyethylene wear rates from AP radiographs Evaluated at 1,3,5,7 ,10th year over 10 years
- Secondary Outcome Measures
Name Time Method Other outcomes that may be relevant. 1,3,5,7,10 yr over 10 years Retrieval analysis 1,3,5,7,10 yr over 10 years Survivorship in subcategories of infection, aseptic loosening and other 1,3,5,7,10 yr over 10 years Subcategories of the outcome scores regarding pain, patient satisfaction, function,general quality of life. 1,3,5,7,10 yr over 10 years
Trial Locations
- Locations (1)
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States